跳至主要内容
临床试验/EUCTR2013-002860-19-NL
EUCTR2013-002860-19-NL进行中(未招募)不适用

The risk of cardiovascular disease in Ankylosing Spondylitis; A Single Center Cross-Sectional Study Evaluating The Association Between Inflammation In Ankylosing Spondylitis And Vascular Inflammation - AS risk

AMC0 个研究点开始时间: 2013年8月15日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
AMC

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Subjects with AS
  • ?Age: =18 years
  • ?Diagnosis of AS (following the 1984 Modified New York Criteria for ankylosing Spondylitis (16)) + disease duration since start of first symptoms for a period of more than 3 years.
  • ?Subject agrees to the restrictions as described in paragraph 4.4.2. In brief: subjects are not permitted any alcohol or caffeine-containing food or drinks from 12 hrs prior to study visits until discharge. In addition, no strenuous exercise is permitted for 24 hrs before the study visits
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Subjects may not enter this study if they meet the following criteria
  • ?BMI > 30.
  • ?History of diabetes mellitus/insulin use
  • ?Hypertension/use of blood pressure lowering medication
  • ?Use of statins prior to inclusion, or contra-indications for statin use.
  • ?History of cardiovascular events
  • ?Proven or suspected bacterial infections. Recent (<1 month prior to screening) or ongoing
  • ?Serious infection requiring IV antibiotic therapy.
  • ?Recent or current treatment with medications that may have a significant effect on plaque Inflammation as measured by plaque TBR, including but not limited to: Biological based medicines (anti-TNF (ex. Infliximab), anti-IL-6 therapy (ex. Tocilizumab) or anti-IL-1 (ex. anakinra)) within 8 weeks before the baseline visit and during the study.
  • ?Any clinically significant medical condition that could interfere with the conduct of the study.
  • ?Standard contra-indications to MRI, 18FDG PET, and CT, including pregnancy and lactating women.
  • ?Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
  • ?Subject has planned cardiac surgery, PCI or carotid stenting, or major non-cardiac surgery during the course of the study period or for 14 days after the last treatment.

研究者

发起方
AMC

相似试验